Tidal Investments LLC grew its position in Centene Co. (NYSE:CNC – Free Report) by 21.8% in the third quarter, HoldingsChannel.com reports. The fund owned 42,117 shares of the company’s stock after buying an additional 7,549 shares during the period. Tidal Investments LLC’s holdings in Centene were worth $3,171,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds also recently modified their holdings of the company. Park Place Capital Corp grew its holdings in Centene by 1,190.0% during the third quarter. Park Place Capital Corp now owns 387 shares of the company’s stock worth $29,000 after purchasing an additional 357 shares during the period. WR Wealth Planners LLC boosted its stake in shares of Centene by 41.4% during the 2nd quarter. WR Wealth Planners LLC now owns 468 shares of the company’s stock worth $31,000 after acquiring an additional 137 shares during the period. Chris Bulman Inc acquired a new position in shares of Centene during the 2nd quarter worth approximately $33,000. Crewe Advisors LLC raised its stake in Centene by 174.3% in the 2nd quarter. Crewe Advisors LLC now owns 683 shares of the company’s stock valued at $45,000 after acquiring an additional 434 shares during the period. Finally, Private Trust Co. NA lifted its stake in shares of Centene by 75.3% during the 3rd quarter. Private Trust Co. NA now owns 773 shares of the company’s stock worth $58,000 after buying an additional 332 shares during the last quarter. 93.63% of the stock is owned by institutional investors.
Centene Stock Performance
NYSE:CNC opened at $59.42 on Friday. The company has a market capitalization of $30.00 billion, a PE ratio of 10.32, a P/E/G ratio of 0.78 and a beta of 0.46. Centene Co. has a fifty-two week low of $55.03 and a fifty-two week high of $81.42. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.10 and a current ratio of 1.10. The company has a 50 day simple moving average of $62.02 and a two-hundred day simple moving average of $68.59.
Insider Transactions at Centene
Analyst Ratings Changes
CNC has been the topic of several recent analyst reports. Wells Fargo & Company decreased their price target on Centene from $91.00 to $90.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Oppenheimer lowered their target price on Centene from $95.00 to $85.00 and set an “outperform” rating for the company in a research note on Friday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $90.00 price target on shares of Centene in a report on Wednesday. Barclays increased their price objective on shares of Centene from $91.00 to $93.00 and gave the company an “overweight” rating in a research note on Friday. Finally, Truist Financial lowered their price target on shares of Centene from $89.00 to $84.00 and set a “buy” rating for the company in a report on Friday. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, Centene has an average rating of “Moderate Buy” and an average price target of $81.31.
Read Our Latest Report on Centene
Centene Profile
Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children’s health insurance program, foster care, medicare-medicaid plans, long-term services and support.
Read More
- Five stocks we like better than Centene
- CD Calculator: Certificate of Deposit Calculator
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Texas Instruments: The Old-School Tech Titan Still Delivering
- Most Volatile Stocks, What Investors Need to Know
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Want to see what other hedge funds are holding CNC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Centene Co. (NYSE:CNC – Free Report).
Receive News & Ratings for Centene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centene and related companies with MarketBeat.com's FREE daily email newsletter.